EKF buys 360 Genomics for a "sensible" £1.6m to move into molecular Dx
This article was originally published in Clinica
Executive Summary
UK firm EKF Diagnostics has made its first foray into the fast-growing molecular diagnostics sector, buying mutation detection specialist 360 Genomics and establishing a new subsidiary, EKF Molecular Diagnostics. The deal adds to EKF's current offering in point-of-care diagnostics, which is focused on diabetes and emerging markets.